Letter to the Editor, T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes resulting from the transformation of T-cell progenitors. Around half of T-ALL patients harbor recurrent cytogenetic alterations, including juxtaposition of strong promoters and enhancers located in the TCRB (chr. 7q34) or TCRA-TCRD (chr. 14q11) loci with a variety of oncogenic transcription factors, such as LIM-only domain (LMO) genes, LMO1 and LMO2 resulting in their aberrant expression. 1 The LIM-only gene LMO2 encodes a protein that participates in a transcription factor complex, which includes E2A, GATA1, and LDB1, TAL1. LMO2 was reportedly activated in 4 cases of T-ALL arising via retroviral insertion mutagenesis in a gene therapy trial for X-linked severe combined immunodeficiency . [2] [3] [4] In addition, aberrant expression of LMO2 has been found in 9% pediatric T-ALL cases, 5 though higher figures have been reported. 6 LMO2 is activated via chromosomal translocations t(11;14)(p13;q11) or t(7;11)(q35;p13) and del(11)(p12p13) in T-ALL patients. 5 Interestingly, high LMO2 expression levels have also been reported in many T-ALL patients without these changes, suggesting that cryptic LMO2 rearrangements may exist in T-ALL. Recently, we identified LMO2 rearrangements in 5/26 (19.2%) T-ALL cell lines including two novel cryptic non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13), respectively activating LMO2 by juxtaposition with MBNL1 and STAG2. 7 This prompted us to investigate novel rearrangements involving LMO2 in primary samples from T-ALL patients using fluorescence in situ hybridization (FISH) with tilepath BAC/fosmid clones, array-comparative genomic hybridization (CGH), and next-generation sequencing (NGS) techniques.
Between July 1997 and April 2013, 409 T-ALL patients were identified following admission to JIH. A total of 264 patients' samples were enrolled into the present study. The median age of the case series was 24 years (range 6-80 years) the majority male (74.6%). T-cell phenotype was defined according to the EGIL criteria.
Conventional R-banding was used for karyotypic analysis on bone marrow (BM) cells at diagnosis. Clonal karyotypic abnormalities were described according to ISCN. 8 We screened all 264 T-ALL patients by FISH using BAC clones on and two with del(11p12). Overall, half of LMO2 rearrangements were cryptic by routine karyotypic analysis at a rate of 4.5% (12/264). LMO2 mRNA expression levels were measured on 10 T-ALL patients with and 39 without LMO2 rearrangements. The qRT-PCR results showed that LMO2 transcripts were significantly higher in cases with LMO2 rearrangements (p=0.02) than without ( Figure 1A) . Meanwhile, the mRNA expression levels of LEF1, LYL1, MEF2C, STAG2, SEPT1, TLX1, and TLX3 were also measured by qRT-PCR in these patients, showing no differences between patients with and without LMO2 rearrangements with the exception of LEF1. Our findings showed that patients with LMO2 rearrangements had higher LEF1 transcripts (p=0.015) ( Figure 1A) , which raises the possibility that LMO2 interactome includes LEF1 in T-ALL, as reported in B-cell lymphomas. 9 Further to explore undetectable cytogenetic abnormalities, we performed integrative genomic and transcriptional analyses on these 24 T-ALL patients with LMO2 rearrangements. FISH with RP11-646J21/278N12 probes revealed del(11p13p13) in six patients including two with del(11p12) according to routine karyotyping ( Table 1) . Array-CGH analysis confirmed respective 95 Kbp and 475 Kbp deletions including the upstream LMO2 region at 11p13 in two T-ALL samples ( Figure 1B) .
Additionally, we performed whole genome sequencing in 2 LMO2 rearranged T-ALL patients (cases 6 and 10) without t(11;14)(p13;q11) or del (11) Figure 1C) . Thus, we identified a rather rare translocation, t(7;11)(q35;p13), in case 6, which has been reported only in a very few T-ALL patients hitherto. 10 In case 10, we identified a fusion between 11p13 (33,957,035 bp) and 14q32
(98,842,615 bp). PCR and bi-directional Sanger sequencing confirmed the presence of chimeric product. The 11p13 breakpoint lay ~43 Kbp upstream of LMO2. The 14q32 breakpoint was located between C14orf64 and C14orf177 genes, ~793 kbp downstream of BCL11B. We recently described a cluster of powerful T-cell enhancers in 3´-BCL11B which can activate homeobox oncogenes NKX2-5 and HOX11L2 by juxtaposition in cytogenetically identical t(5;14)(q35;q32.2). [11] [12] [13] The corresponding region in mice has been shown to control specificity of T-cell expression therein. 14 It is interesting to note that this patient had the highest LMO2 transcription level as shown by qRT-PCR in 49 T-ALL patients mentioned above. We therefore propose that the LMO2 gene is deregulated by juxtaposition with 3´-BCL11B via a novel t(11;14)(p13;q32.2) rearrangement ( Figure 1D ). In T-ALL, cytogenetic alterations juxtaposing LMO2 with strong promoters and enhancers of T-cell receptor loci are recognized as the main activating mechanism. Placement of patient breakpoints often provides clues to the underlying leukemogenic mechanisms involved. The respective breakpoint regions at 11p13/LMO2 and 14q32.2/BCL11B are depicted in Figure 1E .
While the breakpoint at 14q32 lay amid the far distal downstream cluster which we reported previously where NK-family homeobox genes are activated, 13 that at 11p13 lay upstream of those involved in TCR-LMO2 rearrangements where it clustered together with MBNL1 and STAG2 additional non-TCR LMO2 partners which we described recently. 7 FISH analysis with BAC clones in 11p13 and whole chromosome painting confirmed the translocation between LMO2 with the short arm of chromosome 2 in another patient with 47,XY,t(1;1)(p33;q41),t(2;11)(p15;p13),i(7q),+12 [10] (case 15, Figure 1F ).
Chromosome 2p15 has yet to be assigned a recurrent oncogene target in T-ALL to serve as candidate LMO2 partner in this case. Taken together, these findings imply that the imputed activation of LMO2 by non-TCR loci is mechanistically distinct from canonical translocation disease, a conclusion of potential therapeutic relevance.
Interestingly, we identified simultaneous involvement of TCRB and TCRA-TCRD in case 17 by FISH screening. Further FISH characterization indicated that LMO2 is activated via formation of t(7;11)(q35;p13), and MYC via t(8;14)(q24;q11) in this patient ( Figure 1G ).
To determine the association of LMO2 rearrangements with other recurrent gene mutations in T-ALL, we investigated gene mutations by PCR and direct Sanger sequencing in a cohort of 88 T-ALL patients for whom RNA was available, including 13 with LMO2 rearrangements. After excluding known polymorphisms and silent mutations, mutations of FBXW7, IL7R, NOTCH1, PHF6 and WT1 were respectively detected in 8 (9.1%), 4 (4.5%), 40 (45.5%), 12 (13.7%), and 4 (4.5%) of these 88 patients (Supplementary Table 1 ). There were no significant differences in the incidence of FBXW7 (P=0.168), IL7R (P=0.252), NOTCH1 (P=0.956), PHF6 (P=0.265), and WT1 mutated cases (P=0.252) with and without LMO2 rearrangements. We also sequenced the entire coding region of LMO2 in 117 T-ALL patients and found no somatic mutation.
Taken together, LMO2 rearrangements were identified in 9.1% (24/264) of T-ALL patients of which 50% (12/24) were deemed cryptic. The LMO2 transcripts were significantly higher in cases with LMO2 rearrangements than without. Moreover, we detected non-TCR chromosome translocations activating LMO2 in two T-ALL patients,
suggesting that non-TCR chromosome translocations activating LMO2 are recurrent in T-ALL at significant levels. Of note, we identified a novel t(11;14)(p13;q32.2) translocation which activates LMO2 by juxtaposition with remote leukemic enhancers of 3'-BCL11B using whole genome sequencing. Our results indicate that LMO2 is a novel partner gene of BCL11B in T-ALL besides TLX3 and NKX2-5. 
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